DICE News and Press, DICE Therapeutics Inc. From 03/17/23

2023-03-17 16:16:22 ET Summary Here's a long list of biopharmas exposed to SVB Financial Group. Many of these deposits will be uninsured. However, since SVB Financial Group was quite solvent otherwise, much of these deposits should be recoverable by these small companies. ...

2023-03-15 17:10:31 ET DICE Therapeutics press release ( NASDAQ: DICE ): Q4 GAAP EPS of -$0.51 misses by $0.03 . Cash, cash equivalents and marketable securities totaled $574.2 million at December 31, 2022. The Company expects its current cash position to fund operatio...

IND application for DICE’s lead oral IL-17 antagonist, DC-806, cleared by FDA; global Phase 2b clinical trial in patients with moderate-to-severe psoriasis on track to initiate in 1H 2023 First participants dosed in Phase 1 clinical trial of second oral IL-17 antagonist DC-853; topline...

SOUTH SAN FRANCISCO, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic...

SOUTH SAN FRANCISCO, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic ...

Summary DICE Therapeutics rallied hard following positive top-line data in its DC-086 investigational compound in October last year. Momentum has stalled into the new year, however, and we sought to identify how investors are positioning in DICE this year. Data suggests that demand ...

Summary DC-806 is the lead drug for the company, which is being developed as an oral IL-17 drug for psoriasis and other immunological disorders. Proof of concept established with use of DC-806 for patients with psoriasis in a phase 1 study compared to a placebo; Phase 2b study expected ...

Summary Healthcare significantly outperformed the broader market last year, after two years of underperforming the S&P 500. When the end to restrictive policy is in sight, then the sector is likely to witness a group rotation to more growth-oriented stocks. Groups like medical d...

Summary Federal Reserve interest rate policy to again remain the market focus this year and create a chaotic first half. Biotechnology should be favorably positioned relative to the market if the economy slips into a recession. Biotech fortunes near term are to be determined by the ...

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic ...